PFE Pfizer
- Official Name: PFIZER INC.
- Headquarters: 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192 US
- CEO: Albert Bourla
- Website: pfizer.com
- Key Investor: VANGUARD GROUP INC | 9.2%
- Dedicated Investor: PALACIOS WEALTH MANAGEMENT, LLC | 19.04%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 1.971 | 0.917 - (1.054) | ||
| 2025-07-21 | 2 | Won by 1.966 | (2.791) - (4.757) | ||
| 2025-07-28 | 3 | Lost by 1.837 | 0.494 - 2.331 | ||
| 2025-07-29 | 2R | Won by 4.840 | (0.749) - (5.589) | ||
| 2025-08-04 | 4 | Won by 1.423 | (1.722) - (3.145) | ||
| 2025-08-07 | 1R | Won by 1.790 | 1.159 - (0.631) | ||
| 2025-08-11 | 5 | Won by 7.298 TOTW | 6.017 - (1.281) | ||
| 2025-08-12 | 3R | Lost by 2.060 | 0.127 - 2.187 | ||
| 2025-08-18 | 6 | Lost by 1.705 | 1.820 - 3.525 | ||
| 2025-08-20 | 1R | Won by 0.486 | 0.679 - 0.193 | ||
| 2025-08-21 | 2R | Won by 1.160 | 1.163 - 0.003 | ||
| 2025-08-25 | 7 | Lost by 1.016 | 0.920 - 1.936 | ||
| 2025-09-01 | 8 | Lost by 2.214 | (1.467) - 0.747 | ||
| 2025-09-03 | 2R | Won by 0.812 | (0.810) - (1.622) | ||
| 2025-09-04 | 3R | Lost by 2.913 | (1.015) - 1.898 | ||
| 2025-09-08 | 9 | Lost by 6.423 | (0.798) - 5.625 | ||
| 2025-09-15 | 10 | Won by 3.758 | (2.622) - (6.380) | ||
| 2025-09-17 | 3R | Lost by 0.438 | 0.677 - 1.115 | ||
| 2025-09-22 | 11 | Won by 0.018 | 0.282 - 0.264 | ||
| 2025-09-29 | 12 | Lost by 0.180 | (0.781) - (0.601) | ||
| 2025-10-06 | 13 | Won by 7.277 | 7.643 - 0.366 | ||
| 2025-10-13 | 14 | Lost by 0.987 | (6.206) - (5.219) | ||
| 2025-10-20 | 15 | Won by 3.954 | (0.081) - (4.035) |
Latest News
Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)
Pfizer recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and repor...
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends
Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end...
Better Dividend Stock: Pfizer vs. GSK
Key TakeawaysPfizer yields 6. 3% and GSK yields 4.
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand...
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinic...
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readout...
This Company’s Products Kill People, But It Has A 6.2% Yield
Altria's cigarettes kill hundreds of thousands of Americans every year, yet its stock is quietly outperforming the S&P 500 by a wide margin i...
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors pay...
Pfizer Stock Hits 52-Week High: What's Going On?
Pfizer Inc (NYSE:PFE) shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after the FDA approved a T...
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’
CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.
Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?
Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.
How Much Downside Is Left In Liquidia Stock?
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% ...
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
Pfizer (PFE) Gains As Market Dips: What You Should Know
The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.
Better High-Yield Dividend Stock: Pfizer vs. General Mills
Key TakeawaysPfizer yields 6. 3% and General Mills 7.
Better High-Yield Dividend Stock: Pfizer vs. British American Tobacco
Key TakeawaysPfizer yields 6. 3% and British American Tobacco 6.
Better High-Yield Dividend Stock: Pfizer vs. UPS
Key TakeawaysPfizer yields 6. 3% and UPS yields 7.
Better High-Yield Dividend Stock: Pfizer vs. Healthpeak
Key TakeawaysPfizer yields 6. 3% and Healthpeak Properties yields 6.
Better High-Yield Dividend Stock: Pfizer vs. Edison International
Key TakeawaysPfizer yields 6. 3% and Edison International yields 6.
Better High-Yield Dividend Stock: Pfizer vs. Clorox
Key TakeawaysPfizer yields 6. 3% and Clorox yields 6.
Most active S&P500 stocks in Wednesday's session
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks tha...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior manag...
Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline
A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.
Morningstar’s Dividend ETF Is Kind of Perfect for Retirees Right Now
FDL has handed retirees growing income and strong returns for nearly two decades, but the fund comes with a concentrated bet and a quarterly payout qu...
How to Build $9,050 a Month in Dividend Income Without Selling a Single Share
The capital required to collect over $108,000 a year in dividends without selling a share swings by more than $2 million depending on one decision you...
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-202...
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and ...
Final Trades: Thermo Fisher, Pfizer, U.S. 10-year and the XAR
The Investment Committee gives you their top stocks to watch for the second half.
The Open Question Under Johnson & Johnson Stock's Price
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The...
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
BOSTON, October 14, 2026--MindWalk Holdings Corp. (NASDAQ: HYFT) ("MindWalk" or the "Company"), a Bio-Native AI company, today ann...
5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever
Four of these five large-cap dividend stocks just dropped sharply, pushing their yields above 6%, but a rising yield can signal opportunity or a warni...
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked in...
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
NEW YORK, October 14, 2026--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative re...
Pfizer partners with Enodia Therapeutics in $500m drug deal
Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years
Key TakeawaysPfizer yields 6. 3% and Enbridge 6.
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market ex...
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
What Is Pfizer (PFE) Really Gaining From Its Sec61 Drug Discovery Deal?
Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small molecule drugs. Enodia g...
Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You?
Pfizer Inc. (NYSE:PFE) closed at $28.40 on October 12. The stock has returned almost 4% during the last six months, compared to a 21.25% return for th...
Two Mortgage REITs Yield More Than 16%. Their Share Prices Tell Another Story
Five popular income stocks are flashing warning signs that most yield-chasing investors overlook until after the dividend cut. Here is what the covera...
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?
Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers f...
A $750,000 Roth IRA Portfolio Loaded With These Dividend Stocks Pays $47,800 a Year and the IRS Gets None of It
Six high-yield dividend stocks can quietly hand the IRS thousands of dollars every single year, but where you hold them changes everything. The bracke...
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise
Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ...
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
PARIS, October 13, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at th...
Pfizer: The Earnings Test That Matters
Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate. Read more on PFE stock here.
‘Ozempic face’ powers revival of a fading British giant
A surprise discovery may have saved one of Britain’s oldest chemical companies from sliding into irrelevance.
S&P Hits All-Time Highs, AI Trade Does All The Work
From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into ...
Where Could Moderna's Next Growth Come From?
Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales...
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced...
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 throu...
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
How to Play PFE Stock as Pfizer Cuts 300 Jobs
Pfizer is set to cut 330 jobs at its Catania plant as it restructures its business.
Bristol Myers Stock Is Rising on a Double Dose of Good News
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.
Every Roth IRA Needs These High-Yield Dividend Stocks Over 6%
Holding high-yield dividend stocks outside a Roth quietly drains thousands of dollars every year, and the losses compound in a way most investors neve...
4 Blue Chip Giants That May Have to Cut Their Dividends
Four household names are paying dividend yields above 5%, but their earnings, cash flow, and balance sheets tell a different story than their press re...
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations...
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.